Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer

Breast Care ◽

10.1159/000357316 ◽

2013 ◽

Vol 8 (6) ◽

pp. 429-437 ◽

Author(s):

Thomas E. Delea ◽

Carol Hawkes ◽

Mayur M. Amonkar ◽

Konstantinos Lykopoulos ◽

Stephen R. D. Johnston

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Her2 Positive ◽

Menopausal Women ◽

Post Menopausal

Download Full-text

Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer

Current Medical Research and Opinion ◽

10.1080/03007995.2018.1519500 ◽

2018 ◽

Vol 35 (1) ◽

pp. 73-80 ◽

Author(s):

Nicole Princic ◽

Ayal Aizer ◽

Derek H. Tang ◽

David M. Smith ◽

William Johnson ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Systemic Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Menopausal Women ◽

Post Menopausal

Download Full-text

Abstract S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy

10.1158/1538-7445.sabcs16-s1-02 ◽

2017 ◽

Author(s):

NS Kornblum ◽

J Manola ◽

P Klein ◽

B Ramaswamy ◽

A Brufsky ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Double Blind ◽

Menopausal Women ◽

Post Menopausal

Download Full-text

Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor–positive metastatic breast cancer in Canada

Current Oncology ◽

10.3747/co.20.1394 ◽

2013 ◽

Vol 20 (5) ◽

pp. 371 ◽

Author(s):

T.E. Delea ◽

J. Amdahl ◽

A. Chit ◽

M.M. Amonkar

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Her2 Positive ◽

Hormone Receptor Positive

Download Full-text

Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3107-3 ◽

2014 ◽

Vol 147 (2) ◽

pp. 443-443 ◽

Author(s):

Vakaramoko Diaby ◽

Georges Adunlin ◽

Simon B. Zeichner ◽

Kiran Avancha ◽

Gilberto Lopes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

Abstract PD3-08: Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status

10.1158/1538-7445.sabcs20-pd3-08 ◽

2021 ◽

Author(s):

Erika Hamilton ◽

Mattea Reinisch ◽

Sherene Loi ◽

Alicia Okines ◽

Paula R. Pohlmann ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽

Hormone Receptor Status ◽

Her2 Positive ◽

Receptor Status

Download Full-text

Author Correction: Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer

Scientific Reports ◽

10.1038/s41598-018-32881-6 ◽

2018 ◽

Vol 8 (1) ◽

Author(s):

Hai-Yuan Yang ◽

Ding Ma ◽

Yi-Rong Liu ◽

Xin Hu ◽

Jian Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Distant Recurrence ◽

Hormone Receptor Status ◽

Her2 Positive ◽

Receptor Status ◽

Download Full-text

The cost‐effectiveness of trastuzumab emtansine (T‐DM1) in HER2‐positive metastatic breast cancer is supported by clinical evidence

The Breast Journal ◽

10.1111/tbj.14024 ◽

2020 ◽

Author(s):

Jacopo Giuliani ◽

Andrea Bonetti

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Clinical Evidence ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Download Full-text

Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2- Positive Metastatic Breast Cancer (MBC) – Results of theeLEcTRATrial.

10.1158/0008-5472.sabcs-09-4094 ◽

2009 ◽

Author(s):

J. Huober ◽

P. Fasching ◽

S. Paepke ◽

E. Kubista ◽

M. Barsoum ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

Abstract P6-07-32: Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2 positive subtype is associated with the most favorable outcome

10.1158/0008-5472.sabcs12-p6-07-32 ◽

2012 ◽

Author(s):

VCG Tjan-Heijnen ◽

DJA Lobbezoo ◽

RJW van Kampen ◽

AC Voogd ◽

MW Dercksen ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Breast Cancer Subtypes ◽

Favorable Outcome ◽

Her2 Positive ◽

Cancer Subtypes

Download Full-text

Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer

10.1158/1538-7445.sabcs17-ot1-03-06 ◽

2018 ◽

Author(s):

E Shagisultanova ◽

J Diamond ◽

A Stopeck ◽

L Pusztai ◽

R O'Regan ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Her2 Positive ◽

Safety And Efficacy ◽

Phase Ib ◽

Hormone Receptor Positive

Download Full-text